Melanoma Cell State-Specific Responses to TNFα.

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD1) pathway have transformed advanced melanoma treatment.
• Tumor necrosis factor alpha (TNFα), a product of T cell activation, has complex roles in melanoma response and resistance to PD1 inhibitors.

Purpose of the Study:

• To investigate the effect of TNFα on melanoma dedifferentiation, antigen presentation, and immune inhibition.
• To understand how TNFα signaling influences melanoma cell behavior in the context of immunotherapy.

Main Methods:

• Analysis of TNFα signaling in a panel of 40 melanoma cell lines.
• Assessment of TNFα's impact on melanoma dedifferentiation markers.
• Evaluation of TNFα's effect on antigen presentation molecules (HLA-ABC, HLA-DR) and immune checkpoint ligand (PD-L2) expression.

Main Results:

• TNFα signaling is present in all tested melanomas.
• The downstream effects of TNFα depend on the differentiation status of melanoma cells.
• TNFα poorly induces HLA-ABC and HLA-DR but effectively induces PD-L2 expression in melanoma cells.

Conclusions:

• TNFα induces changes in melanoma cells that may contribute to resistance against immunotherapy.
• Targeting TNFα or its downstream effects could be a strategy to overcome immunotherapy resistance in melanoma.